RYZ802
Pancreatic Cancer
DiscoveryActive
Key Facts
About RayzeBio
RayzeBio is a San Diego-based radiopharmaceutical company founded in 2020, specializing in targeted alpha therapies using actinium-225. The company has built a pipeline of drug candidates aimed at various solid tumors and was acquired by Bristol Myers Squibb, indicating strong validation of its platform and pipeline. RayzeBio's approach combines a proprietary targeting moiety with a potent radioactive payload to deliver precise, tumor-killing radiation while aiming to minimize damage to healthy tissues.
View full company profileTherapeutic Areas
Other Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| HBM9027 | Harbour BioMed | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| AHPBA IRE Registry | AngioDynamics | Post-Market Registry |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Pritumumab (PTB) | Nascent Biotech | Phase II (Planned) |
| Pancreatic Cancer Test | Mosaique Diagnostic | Development |
| Iontophoretic System | Continuity Biosciences | Pre-clinical |
| Lixumistat (IM156) | ImmunoMet Therapeutics | Phase 1b |